TP53 and acute myeloid leukemia: With regards to overall survival, patients with “AML with mutated TP53” had a dismal prognosis with a 2-year OS of 6%, followed by “AML with myelodysplasia-related gene mutations”, “AML with mutated NPM1”, “AML with myelodysplasia-related cytogenetic abnormalities” with 2-year OS rates of 13%, 18%, 21%, respectively (Supplementary Table S6).